The goal ofthe University of lowa / Mayo Clinic Lymphoma SPORE (UI/MC SPORE) Developmental Research Program is to support innovative, scientifically sound projects that investigate a question pertaining to translational lymphoma research. This program was highly successful with past and current support over the past 4 years going to 13 developmental research projects. Three of these projects have received external, peer-reviewed NCI funding or a fundable priority score, 3 received a second year of funding, and 3 provided data that was instrumental for the major research projects selected for this renewal. The Developmental Research Program will provide up to $50,000 for one year ($25,000 from UI/MC SPORE funds and a matching $25,000 from institutional resources) to each of four projects each year with the possibility of a second year of support based on progress. It is anticipated that support of developmental research projects will continue to result in the generation of new hypotheses that will be tested in full UI/MC SPORE-sponsored projects or through peer reviewed external grant support. The long-term goal of the UI/MC SPORE program is to translate the findings generated by developmental projects into a reduction in the incidence and mortality rates of lymphoma. More specifically, the objectives ef the Developmental Research Program are to: (1) encourage innovative translationally-relevant laboratory, population and clinical studies in lymphoma and chronic lymphocytic leukemia;(2) foster extensive collaboration between basic science, population science and clinical disciplines in translational research in lymphoma;and, (3) generate new hypotheses to be tested in large-scale research projects or clinical trials that may lead to significant reduction of lymphoma incidence and mortality. Brief outlines of four developmental research projects from investigators at the University of lowa and the Mayo Clinic are included to demonstrate the depth and breadth of ongoing research that can be applied to the translational lymphoma research at these institutions and could be eligible for UI/MC SPORE Developmental Program support.

Public Health Relevance

The UI/MC SPORE in Lymphoma Developmental Research Program (DRP) was established to fund early phase research that takes maximum advantage of UI/MC SPORE resources to generate feasibility data for projects that have the highest translational potential. The DRP encourages proposals from investigators in related disciplines se as to rapidly translate new treatment concepts to patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA097274-11
Application #
8395839
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
2002-09-11
Project End
2017-06-30
Budget Start
2012-09-12
Budget End
2013-06-30
Support Year
11
Fiscal Year
2012
Total Cost
$160,832
Indirect Cost
$26,202
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Link, Brian K (2017) Early Relapse in Follicular Lymphoma: High Risks and High Stakes. J Oncol Pract 13:810-811
Ding, Wei; LaPlant, Betsy R; Call, Timothy G et al. (2017) Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood 129:3419-3427
Ammann, Eric M; Shanafelt, Tait D; Larson, Melissa C et al. (2017) Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clin Lymphoma Myeloma Leuk 17:e11-e25
Wafa, Emad I; Geary, Sean M; Goodman, Jonathan T et al. (2017) The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response. Acta Biomater 50:417-427
Paulus, A; Akhtar, S; Yousaf, H et al. (2017) Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J 7:e565
Tanaka, Yoshimasa; Iwasaki, Masashi; Murata-Hirai, Kaoru et al. (2017) Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug. Sci Rep 7:5987
Wang, Xueju; Dasari, Surendra; Nowakowski, Grzegorz S et al. (2017) Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma. Oncotarget 8:26245-26255
Scott, David W; Abrisqueta, Pau; Wright, George W et al. (2017) New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. J Clin Oncol 35:1668-1677
Tracy, S I; Maurer, M J; Witzig, T E et al. (2017) Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma. Blood Cancer J 7:e595
Law, Philip J; Berndt, Sonja I; Speedy, Helen E et al. (2017) Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nat Commun 8:14175

Showing the most recent 10 out of 337 publications